14 September 2018
US FDA approves Lumoxitifor certain patients with relapsed or refractory hairy cell leukaemia. Approval of Lumoxiti, a first-in-class medicine for hairy cell leukaemia marks first new treatment option for patients in over 20 years. …
Further to the ordinary shareholder class meeting on 5 September 2018, whereby the Ordinary Share Distribution Policy was amended to permit the Directors to effect the Minimum Annual Distribution by repurchasing ordinary shares of 0.0001 pence each on an ongoing basis each quarter….
Photo-Me, the instant-service equipment group, announces that it has completed the sale of its 50% stake in Stilla Technologies SA, a Paris-based European Biotechnology company….
Acquisitions and Placing of New Ordinary Shares…
PRELIMINARY RESULT – For the 52 weeks ended 29 July 2018…
13 September 2018
INTERIM RESULTS FOR THE HALF YEAR TO 5 AUGUST 2018…
13 September 2018 -COLEFAX GROUP PLC – AGM STATEMENT…
Acquisition of Systagenix Wound Management Manufacturing Limited Acquisition of development and manufacturing assets of Systagenix Entering a 5-year exclusive manufacturing and supply agreement…